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Negatively charged low-density lipoprotein (LDL), generated via multiple processes 
such as oxidation, acetylation, or glycosylation, plays a key role in the initiation and 
progression of atherosclerosis and related diseases. Anion-exchange high performance 
liquid chromatography (AE-HPLC) can subfractionate LDL into LDL-1, LDL-2 and LDL-3 
based on LDL particle charge, but the clinical significance of LDL subfractions has not yet 
been elucidated. The aim of this study was to determine the clinical significance of these 
fractions with particular regard to atherogenic risk in hypertensive patients. 
Ninety-eight patients with essential hypertension (age, 67.0 ± 10.7 years; 54 males) 
were enrolled in the present study. The relationships between LDL subfractions and 
atherogenic risk factors, including lipid profiles, blood pressure and plasma 8-isoprostane 
as a marker of oxidative stress, were examined. 
LDL-1 levels significantly and negatively correlated with body mass index (r = -0.384, 
p < 0.001), systolic blood pressure (r = -0.457, p < 0.001), non-high-density lipoprotein 
cholesterol levels (r = -0.457, p < 0.001) and 8-isoprostane levels (r = -0.415, p < 0.001). 
LDL-3, which is the most negatively charged fraction of total LDL, significantly and 
positively correlated with these parameters (r = 0.267, 0.481, 0.357, and 0.337, 
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respectively). LDL-1 levels were significantly lower (p < 0.001), and LDL-2 and LDL-3 
levels were significantly higher (each p < 0.001) in patients with poorly controlled 
hypertension than in patients with well-controlled hypertension. In addition, an increase in 
the total number of traditional risk factors at time of study participation, but not previous 
diagnosis, was associated with a decrease in LDL-1 levels and increases in LDL-2 and 
LDL-3 levels. These data suggest that LDL subfractions are associated with multiple 
atherogenic risk factors and that treatment to modify these risk factors could result in 
changes in LDL subfraction levels. In conclusion, LDL subfractions isolated by AE-HPLC 
may represent a marker of atherogenic risk in patients with hypertension. 
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Growing evidence from both in vivo and in vitro studies shows that the qualitative 
rather than quantitate proprieties of low-density lipoprotein (LDL) plays a key role in the 
initiation and progression of atherosclerosis.(1-5)  LDL particles are heterogeneous in 
density, size and chemical composition, and LDL size correlates positively with 
high-density lipoprotein (HDL) levels and negatively with triglycerides levels. Small dense 
LDL is an atherogenic lipoprotein and has been designated as an emergent cardiovascular 
risk factor by the National Education Program Adult Treatment Panel III (NCEP ATP 
III).(3)  The atherogenicity of small dense LDL is related to its susceptibility to oxidative 
modification.(3, 6, 7)  Oxidative modification can change the charge property of particles 
(8), and negatively charged LDL exerts various proatherogenic effects and properties, 
including cytotoxity, increased leukocyte recruitment, and impaired angiogenesis and LDL 
receptor binding.(9) 
Negatively charged LDL, which is generated through a peroxidative process, contains 
more lipoperoxides and cholesterol oxides and less -tocopherol than native LDL.(10-14)  
In contrast, Sánchez-Quesada et al.(15) reported that the proportion of malondialdehyde, 
fatty acid hydroxides and antioxidants in negatively charged LDL is similar to that in 
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positively charged LDL.  Thus, there are some discrepancies among reports of the 
physiochemical characteristics of negatively charged LDL. Based on previous reports, the 
concentrations of malondialdehyde-modified LDL (MDA-LDL) or oxidized LDL (oxLDL), 
(i.e., oxidized forms of LDL) in total LDL are considerably lower than that of negatively 
charged LDL (0.1 to 0.5% vs. 1 to 10%, respectively),(10-17) suggesting that most 
negatively charged LDL has not been generated by oxidative modification. Indeed, a 
variety of processes and factors, including oxidation, acetylation, nonenzymatic 
glycosylation, enrichment of non-esterified fatty acid, platelet activating factor 
acetylhydrolase, and enzymatic modification by phospholipase A2, can modify native LDL 
to negatively charged LDL.(18)  In human studies, an increase of negatively charged LDL 
is associated with a high incidence of cardiovascular events in patients with 
hypercholesterolemia,(19-21) hypertriglyceridemia,(22) diabetes(23-26) or renal 
failure.(27)  Thus, negatively charged LDL may be generated through multiple processes 
related to atherogenesis. 
It is currently possible to isolate negatively charged LDL from plasma.  Two 
techniques are used to separate LDL by electrical charge: ion-exchange chromatography(22, 
28) and capillary isotachophoresis (cITP).(29, 30)  An assay of LDL subfractions using 
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anion-exchange high performance liquid chromatography (AE-HPLC), in which LDL is 
subfractionated into LDL-1, LDL-2 and LDL-3 in order of increasing particle 
electronegativity, has been developed,(31, 32) whereas previous evaluations by 
ion-exchange chromatography could only isolate two subfractions (i.e., negatively or 
positively charged LDL).  This technique was based on the finding that extensive 
fragmentations of apolipoprotein B by oxidation are associated with increased negative 
charge in LDL particles.(32)  Furthermore, Bittolo-Bon and Cazzolato used ion-exchange 
HPLC as a standard technique measuring negatively charged LDL and reported the 
presence of the faster subfraction in cITP strongly correlated to plasma concentration of 
negatively charged LDL by ion-exchange HPLC.(33)  Thus, we used AE-HPLC to 
measure electronegativity of LDL in this study. 
The significance of negatively charged LDL in humans has been elucidated in patients 
with a known high-risk of atherogenesis but not in patients with hypertension. Thus, the 
goal of this study was to characterize the utility of negatively charged LDL isolated by 





Materials and Methods 
This study enrolled 98 patients with essential hypertension (defined as undergoing 
treatment with antihypertensive agents, or as systolic blood pressure of ≥140 mmHg and/or 
diastolic blood pressure of ≥90 mmHg on two recent measurements). Blood pressure was 
measured using a mercury sphygmomanometer in the seated position after 5 min at rest. 
Poorly controlled hypertension was defined as systolic blood pressure ≥140 mmHg 
and/or diastolic blood pressure ≥90 mmHg, while well-controlled hypertension was defined 
as systolic blood pressure <140 mmHg and diastolic blood pressure of <90 mmHg in 
response to antihypertensive agents. Poorly controlled dyslipidemia was defined as 
LDL-cholesterol (LDL-C) ≥140 mg/dl, triglycerides ≥150 mg/dl or high-density lipoprotein 
cholesterol (HDL-C) <40 mg/dl with or without lipid-lowering agents. Poorly controlled 
diabetes was defined as fasting blood glucose ≥126 mg/dl or hemoglobin A1c (HbA1c) 
≥6.5% with or without anti-diabetes medications. Patients with severe liver, renal or 
respiratory diseases, active infectious and inflammatory diseases, acute heart failure, 
unstable angina or secondary hypertension were excluded from the study. The Ethics 
Committee of Nagasaki University School of Medicine approved the study, which also 
conformed to the Declaration of Helsinki. All patients provided written, informed consent 
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to participate in all procedures associated with the study. 
Body mass index (BMI) was calculated as weight/height2 (kg/m2). Blood samples were 
obtained from the antecubital vein in the morning after an overnight fast. Hematological 
and biochemical parameters, including lipid profiles, fasting blood glucose and HbA1c, 
were analyzed. 
Subfractions of LDL in plasma were measured by AE-HPLC using an 
industry-standard analytical platform (SRL, Inc., Tokyo, Japan) as previously 
described.(31)  This method chromatographically subfractionates LDL in a stepwise 
manner on a ProtEx-DES anion-exchange column in order of increasing electronegativity 
into LDL-1, LDL-2 and LDL-3 subfractions. The amount of each fraction is described as a 
ratio (%) of the total LDL level. Total plasma levels of 8-isoprostane, used as a marker of 
oxidative stress, and highly sensitive C-reactive protein (hs-CRP), as a marker of 
inflammation, were also measured using an industry-standard analytical platform (SRL, 
Inc.). 
We examined the relationship between LDL subfractions and atherogenic risk factors 
and whether treatment for atherogenic risk factors affected the levels of LDL subfractions. 
Data were statistically analyzed using SPSS II version 11 software (SPSS Inc., Chicago, 
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IL, USA). Relationships between variables were determined by Pearson’s correlation 
analysis. Differences between two groups were analyzed using unpaired Student’s t-test. 
LDL subfractions levels vs. number of atherogenic risk factors were compared using 
repeated measures ANOVA, followed by the Bonferroni post hoc test. Data are presented as 





Patient characteristics are summarized in Table 1. The average age was 67.0 years, and 
most patients received antihypertensive medications. 
Systolic and diastolic blood pressure positively correlated with LDL-1 and negatively 
correlated with LDL-2 and -3 (Figure 1). BMI, LDL-C, and 8-isoprostane were 
significantly higher in patients with poorly controlled hypertension than in patients with 
well-controlled hypertension (Table 2). Further, LDL-1 levels were significantly lower (p < 
0.001) and LDL-2 and LDL-3 levels were significantly higher (each p < 0.001) in patients 
with poorly controlled hypertension than in patients with well-controlled hypertension 
(Figure 2). As summarized in Table 3, BMI, non-HDL-C, and 8-isoprostane positively 
correlated with LDL-1 levels and negatively correlated with LDL-2 and LDL-3 levels. 
Fasting blood glucose and HbA1c were weakly, but significantly, correlated with LDL-3 
levels. In contrast, hs-CRP did not correlate with LDL subfraction levels. 
Because multiple atherogenic risk factors were associated with LDL subfractions, the 
relationship between LDL subfractions levels and the number of traditional risk factors 
(e.g., hypertension, dyslipidemia and diabetes mellitus) was assessed. As the number of risk 
factors present at the time of study evaluation increased, LDL-1 decreased significantly and 
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LDL-2 increased significantly. LDL-3 levels were significantly higher in patients with two 
or three risk factors than in those with no risk factors. In contrast, there were no significant 
differences in LDL subfraction levels based on the number of previously diagnosed risk 





The present study evaluated the significance of LDL subfractions, specifically, 
negatively charged LDL separated by AE-HPLC, in patients with essential hypertension 
and found an association between LDL subfractions and atherogenic risk factors, including 
blood pressure, non-HDL-C, BMI, and 8-isoprostane. Furthermore, as the number of 
atherogenic risk factors diagnosed at time of study (but not previous diagnoses) increased, 
LDL-1 levels decreased and LDL-2 and LDL-3 levels increased. 
Negatively charged LDL is generated by various processes and leads to 
atherosclerosis.(18)  Oxidation of LDL is one of these processes. Avagato and colleagues 
reported that negatively charged LDL was associated with decreased vitamin E content, 
increased thiobarbituric acid reactive substances and conjugated dienes, and poor affinity 
towards LDL receptors.(13, 14)  Increasing oxidative susceptibility and decreasing 
concentrations of antioxidants is associated with decreasing LDL size.  Smaller LDL is 
taken up more easily by arterial tissues and is associated with decreased receptor-mediated 
uptake and increased proteoglycan binding.(3)  The negatively charged LDL content is 
higher in the dense LDL fraction than in the light LDL fraction.(34)  Thus, small dense 
LDL, which is an atherogenic phenotype of lipoprotein, is associated with negatively 
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charged LDL.  Indeed, Noda, et al.(35) demonstrated that negatively charged LDL isolated 
by cITP was present within the small dense LDL fraction.  A recent study has 
demonstrated that negatively charged LDL was internalized via the lectin-like oxidized 
LDL receptor (LOX-1), which is an oxidized LDL receptor in endothelial cells. This 
process resulted in impairments of Akt-mediated growth and survival signals.(36) 
Experiments that use the AE-HPLC technique to separate LDL by particle 
electronegativity have shown that decreasing concentrations of LDL-1 and increasing 
concentrations of LDL-2 or LDL-3 reflect oxidative LDL modification.(31, 32, 37-40)  
Yamaguchi et al.(32) found that LDL-1 levels decreased and LDL-3 levels increased when 
LDL oxidative status was increased by incubating native LDL from rabbit plasma with 5 
μM CuCl2 for various periods. Moreover, Watanabe heritable hyperlipidemic rabbits have 
higher levels of LDL-2, LDL-3 and thiobarbituric acid reactive substances (a marker of 
lipid peroxidation) than normolipidemic Japanese white rabbits, and concentrations of total 
hydroxyoctadecadienoic acid, 7α- and 7β-hydroxycholesterol and 8-isoprostane, which are 
biomarkers of lipid peroxidation, are higher in LDL-3 than in LDL-1 and LDL-2 in human 
plasma.(31)  In the present study, 8-isoprostane levels were negatively correlated with 
LDL-1 and positively correlated with LDL-2 and -3, and blood pressure values correlated 
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with LDL subfractions in a similar manner.  Elevated blood pressure induces an increased 
mechanical stretch force on vessel walls, which results in an increased production of 
reactive oxygen species via the NADPH oxidase system.(41, 42)  Furthermore, 
angiotensin II also causes hypertension by producing reactive oxygen species via the 
NADPH oxidase system.(43)  Thus, oxidative stress is considered to be a cause and/or a 
consequence of hypertension.  Conversely, antioxidants, such as superoxide dismutase and 
tempol (4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl), decrease blood pressure in 
spontaneously hypertensive rats but not in normal rats.(44)  In a preliminary study, 
lowering blood pressure with olmesartan, an angiotensin II receptor blocker, increased 
levels of serum LDL-1, decreased levels of serum LDL-2 and LDL-3, and decreased 
plasma 8-isoprostane levels at 3 and 6 months (data not shown).  In addition, negatively 
charged LDL subfractions were lower in patients with hypertension than in those with 
blood pressure that was well controlled by antihypertensive medications (Figure 2).  This 
suggests that appropriate treatment of this risk factor resulted in lower levels of negatively 
charged LDL.  Thus, elevated blood pressure-induced oxidative modification may be 
associated with reversible changes in negatively charged LDL levels. 
This study also demonstrated that the total number of risk factors present upon 
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examination in this study (but not previous diagnoses) correlated with LDL subfraction 
levels.  Given the findings in Table 3, this suggests that negatively charged LDL is related 
to various atherogenic risk factors that are currently or recently present among the patient 
population. 
There was no relationship between hs-CRP and LDL subfractions in this study.  
Indeed, inflammation is a known modifier of electronegativity.(18, 28)  Because the 
average level of hs-CRP in our patients was higher than that reported in previous studies of 
patients with atherosclerosis,(45, 46) some of the patients in the present study population 
may have subclinical inflammation other than that related to atherosclerosis, and this may 
have obscured the relationship between hs-CRP and LDL subfraction levels. 
Limitations 
This study was conducted in a small cohort. Levels of 8-isoprostane were used as a 
marker of oxidative stress for comparison with LDL subfractions. Other markers of 
oxidative stress, such as malondialdehyde-modified LDL, hydroxyoctadecadienoic acid and 
8-hydroxydeoxyguanosine, may be required for further corroboration. Although smoking is 
highly associated with oxidative stress,(38) we found no relationships between smoking 
and LDL subfractions, possibly because we did not assess the extent of smoking in our 
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patients (i.e., packs-per-day, duration, etc.).  Levels of small dense LDL are higher in 
patients with hypertension than in those without hypertension.(47)  However, the present 
study did not assess small dense LDL levels and therefore cannot describe the relationship 
between small dense LDL levels and negatively charged LDL.  Given that small dense 
LDL is a component of non-HDL cholesterol, our finding of a significant correlation 
between LDL subfractions isolated by AE-HPLC and non-HDL cholesterol may reflect the 
association between small dense LDL and negatively charged LDL. 
This study assessed the association between negatively charged LDL and atherogenic 
risk factors. However, a prospective study would be required to definitely establish the 
clinical utility of LDL subfractions in predicting cardiovascular events. Regardless, we 
demonstrated that LDL subfractions were associated with multiple atherogenic risk factors 
related to oxidative modification in patients with essential hypertension. Since these risk 
factors have already been validated as good predictors of cardiovascular events, the present 
data already support the significance of LDL subfractions in the clinical setting to some 
extent. 
In conclusion, LDL subfractions isolated by AE-HPLC may represent a marker of 
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Figure 1. Correlations between 
blood pressure and LDL 
subfractions. Closed circles and 
triangle indicate systolic and 
diastolic blood pressure, 





Figure 2. Levels of LDL 
subfractions in individuals with 
poorly and well-controlled 
hypertension. Box plots indicate 
levels of LDL-1 (a), LDL-2 (b), and 
LDL-3 (c). Center horizontal lines 
indicate median values; upper and 
lower edges of outer boxes, 25th and 
75th percentiles; lower and upper 





Figure 3. Comparisons of 
the levels of LDL 
subfractions in patients 
with different numbers of 
atherogenic risk factors, as 
assessed by previous 
diagnosis or current 
evaluation. White and 
black bars indicate the 
levels of LDL subfractions 
assessed by previous 
diagnosis and current data, 
respectively. Values are 
presented as means  SD. *p 
< 0.01, †p < 0.05. 
 
Table 1.  Characteristics of patients 
 
Parameters Mean ± SD 
Age (years) 67.0 ± 10.7 
Gender (male : female) 54 : 44 
Body mass index (kg/m2) 24.5 ± 4.4 
Diabetes mellitus (%) 34.7 
Dyslipidemia (%) 48.0 
Smoking (%) 43.9 
Systolic blood pressure (mmHg) 133.0 ± 19.7 
Diastolic blood pressure (mmHg) 74.1 ± 12.5 
LDL-cholesterol (mg/dl) 108.5 ± 26.3 
Triglyceride (mg/dl) 116.4 ± 50.8 
HDL -cholesterol (mg/dl) 49.9 ± 11.9 
Fasting blood glucose (mg/dl) 102.5 ± 20.7 
Hemoglobin A1c (%) 5.75 ± 0.61 
high-sensitive CRP (mg/L) 3.69 ± 8.23 
Anti-hypertensive medications use (%) 96.9 
Calcium channel antagonists (%) 55.1 
ACE-I / ARB (%) 65.3 
α receptor blocker (%) 11.2 
β receptor blocker (%) 28.6 
Diuretics (%) 20.4 
Statin use (%) 45.9 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive protein; 
ACE-I, Angiotensin-converting enzyme inhibitors; ARB, Angiotensin receptor blockers. 




(n = 64) 
Poorly controlled
(n = 34) 
Age (years) 66.8 ± 10.7 67.3 ± 10.7 
Gender (male : female) 39 : 25 15 : 19 
Body mass index (kg/m2) 23.8 ± 4.2 25.9 ± 4.4† 
Diabetes mellitus (%) 39.1 26.5 
Dyslipidemia (%) 50.0 44.1 
Smoking (%) 54.7 23.5* 
Systolic blood pressure (mmHg) 121.7 ± 11.2 154.3 ± 13.4* 
Diastolic blood pressure (mmHg) 69.0 ± 8.7 83.6 ± 13.1* 
LDL-cholesterol (mg/dl) 105.3 ± 30.6 117.5 ± 23.6† 
Triglyceride (mg/dl) 114.7 ± 50.4 119.7 ± 52.2 
HDL -cholesterol (mg/dl) 48.8 ± 12.2 51.9 ± 11.1 
Fasting blood glucose (mg/dl) 103.3 ± 22.2 101.1 ± 17.9 
Hemoglobin A1c (%) 5.75 ± 0.64 5.72 ± 0.57 
high-sensitive CRP (mg/L) 4.74 ± 9.88 1.72 ± 2.59† 
Anti-hypertensive medications use 
(%) 
100.0 91.2 
Calcium channel antagonists (%) 53.1 58.8 
ACE-I/ ARB (%) 73.4 50.0† 
α receptor blocker (%) 7.8 17.7 
β receptor blocker (%) 32.8 20.6 
Diuretics (%) 26.6 8.8† 
Statin use (%) 53.1 32.4† 
8-isoprostane (pg/ml) 12.9 ± 3.1 14.8 ± 5.1† 
Uric acid (mg/dl) 5.85 ± 1.37 5.94 ± 1.52 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive protein; 
ACE-I, Angiotensin-converting enzyme inhibitors; ARB, Angiotensin receptor blockers. 
*p < 0.01, †p < 0.05. 
 
Table 3. Correlations between LDL subfractions and atherogenic risk factors  
 
parameters  LDL-1 LDL-2 LDL-3 
r P value r P value r P value 
Body mass index  -0.384 p < 0.001 0.396  p < 0.001 0.267 p = 0.012 
Non-HDL-C  -0.403 p < 0.001 0.398  p < 0.001 0.357 p < 0.001 
Fasting blood glucose -0.187 p = 0.067 0.165  p = 0.106 0.274 p = 0.007 
HbA1c  -0.143 p = 0.207 0.120  p = 0.288 0.244 p = 0.029 
Uric acid  0.125 p = 0.237 -0.125  p = 0.235 -0.091 p = 0.391 
high sensitive CRP 0.088 p = 0.390 -0.097  p = 0.343 -0.035 p = 0.733 
8-isoprostane  -0.415 p < 0.001 0.412  p < 0.001 0.337 p = 0.001 
 
